Aspen Neuroscience, Inc., a clinical-stage biotech developing autologous regenerative therapies, announced the start of Cohort 3 in its ASPIRO Phase 1/2a trial of ANPD001 for Parkinson’s disease (PD).
This milestone marks the first use of Aspen’s commercial-ready formulation of ANPD001, engineered for scalability, reproducibility, and streamlined hospital workflows.
Cohort 3: A Step Toward Commercial Readiness
- Continuity assured – The new formulation is preclinically comparable to earlier cohorts.
- Streamlined delivery – Cryopreserved cells are ready for dosing immediately on arrival, easing the burden on hospital labs.
- Positive foundation – Previous cohorts showed strong safety, tolerability, and early efficacy signals without immunosuppression.
“Cohort 3 represents an important step toward commercial readiness. We’ve optimized our formulation and delivery system to meet the demands of late-stage development and future market access.”
- Damien McDevitt, Ph.D., President and CEO.
The Three Pillars of Aspen’s Approach
Aspen’s commercial formulation reflects an integrated innovation platform:
- Manufacturing Platform – Converts patient skin cells into dopaminergic neuronal precursor cells (DANPCs) using machine learning for consistent quality.
- Therapeutic Platform – ANPD001 is an autologous iPSC-derived DANPC therapy that avoids immune rejection and immunosuppression.
- Proprietary Delivery Device – Precision transplantation with metered dosing and MRI guidance ensures sub-millimeter accuracy and minimally invasive surgery.
“Together, these three pillars form a platform that is personalized, precise, and scalable.”
- Lisa Johnson-Pratt, M.D., EVP, Therapeutic Program Lead.
Why ANPD001 Stands Out
Unlike allogeneic therapies that rely on donor cells, ANPD001 uses a patient’s own cells. This eliminates the need for immunosuppressive drugs, avoids related side effects, and opens eligibility for patients contraindicated for IS therapy.
With over 1 million people in the U.S. living with Parkinson’s and no disease-modifying therapies available, ANPD001 offers the potential to restore lost dopaminergic function—with curative intent.
About ANPD001
- Most advanced autologous PD therapy in the U.S.
- FDA Fast Track designation granted.
- Developed from a patient’s skin cells, reprogrammed into iPSCs, and differentiated into DANPCs.
- Transplanted into the posterior putamen to replace damaged or lost neurons.
- Quality safeguarded with Aspen’s machine learning–based genomic tests at every stage.
About the ASPIRO Trial
ASPIRO is the first multi-patient, multi-center trial of an autologous cell therapy for Parkinson’s. It evaluates safety, tolerability, and early efficacy of ANPD001 in levodopa-responsive patients aged 50–70.
- Primary endpoints: 12 months.
- Long-term follow-up: Up to 15 years.
- ClinicalTrials.gov ID: NCT06344026.
